en · de · es · fr · pt
thymosin-alpha-1-notes.peptides4800.com › Data › Research History And Clinical Assessment — Worked Examples

Research History And Clinical Assessment — Worked Examples

By Editorial Desk · published 2025-07-30 · last reviewed 2025-08-18 · Data

If you have been reading about Thymalfasin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-08-18. Where a claim depends on a specific study, the study is described rather than over-claimed.

Research History and Clinical Assessment

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.

Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.

Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.

Background and Molecular Identity

Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.

The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.

Thymosin-alpha-1 at a glance

PropertyValueNotes
First described1977Reported as a component of thymosin fraction 5
Sequence length28 amino acidsN-terminal residue is acetylated
Net charge at neutral pHNegativeReflects a high proportion of acidic residues
Principal studied usesChronic hepatitis B and vaccine adjuvantResearch uses outnumber approved indications
Regulatory statusApproved in a limited number of countriesNot approved in the United States or most of Europe

Molecular Background and Immune Action

Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.

Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.

Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.

Related pages on this site

分子身份与天然来源

20世纪70年代,研究者从胸腺提取物中纯化出多种小肽,Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤,产量低且成分复杂。随着固相肽合成技术成熟,实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上,并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。

市售的胸腺素α1通常以冻干粉形式提供,溶解后用于注射。其氨基酸组成包括多个酸性残基,因此在中性pH下带负电荷。该肽可溶于水和生理盐水,但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度,溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。

Handling, Storage, and Analytical Verification

Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.

Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.

Molecular Identity Of Thymosin Alpha-1

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Notes from published material

OSB/0 – No added formaldehyde OSB/1 – General-purpose boards and boards for interior fitments (including furniture) for use in dry conditions OSB/2 – Load-bearing boards for use in dry conditions OSB/3 – Load-bearing boards for use in humid conditions OSB/4 – Heavy-duty load-bearing boards for use in humid conditions

Octopus vulgaris grows to 25 cm (10 inches) in mantle length with arms up to 1 m (3.3 feet) long. It lives for 1–2 years and may weigh up to 9 kg (20 pounds). Mating may become cannibalistic. O. vulgaris is caught by bottom trawls on a huge scale off the northwestern coast of Africa. More than 20,000 tonnes (22,000 short tons) are harvested annually. The common octopus hunts at dusk. Crabs, lobsters, and bivalve mollusks (such as cockles) are preferred, although the octopus eats almost anything it can catch. It is able to change colour to blend in with its surroundings, and is able to jump upon any unwary prey that wanders across its path. Using its beak, it is able to break into the shells of shelled mollusks. It also possesses venom to subdue its prey. They have evolved to have large nervous systems and brains. An individual has about 500 million neurons in its body, almost comparable to dogs. They are intelligent enough to distinguish brightness, navigate mazes, recognize individual people, learn how to unscrew a jar or raid lobster traps. They have also been observed keeping "gardens", in which they collect various marine plant life and algae, alongside collections of shells and rocks; this behavior may have inspired the 1969 Beatles title, "Octopus' Garden". O. vulgaris was the first invertebrate animal protected by the Animals (Scientific Procedures) Act 1986 in the UK. Training experiments have shown the common octopus can distinguish the brightness, size, shape, and horizontal or vertical orientation of objects.

This term acquired a pejorative connotation in 18th-century Russia, and it currently means "petty bourgeois" or "narrow-minded philistine". The entire city of the late 17th century is contained within contemporary Moscow's Central Administrative Okrug. Numerous disasters befell the city during this period. Plague epidemics ravaged Moscow in 1570–1571, 1592, and 1654–1656. The plague killed more than 80% of the population in 1654–1655. Fires burned down much of the wooden city in 1626 and 1648. In 1712, Peter the Great moved his government to the newly built city of Saint Petersburg on the coast of the Baltic Sea.

Sources: en.wikipedia.org

Further detail

=== Mass spectrometry === Mass spectrometry (MS) is helpful for the determination of the molecular weight of the polymer, structure of the polymer, etc. Although chemists utilize many kinds of MS, the two that are used most typically are matrix-assisted laser desorption ionization/time of flight (MALDI-TOF) and electrospray ionization-mass spectroscopy (ESI-MS). One of the biggest disadvantages of this technique is that much like NMR spectroscopy the polymers have to be soluble in some organic solvent. An advantage of using MALDI is that it provides the simpler data to interpret for end group identification compared with ESI, but a disadvantage is that the ionization can be rather hard and as a result some end groups do not remain intact for analysis. Because of the harsh ionization in MALDI, one of the biggest advantages of using ESI is for its "softer" ionization methods. The disadvantage of using ESI is that the data obtained can be very complex due to the mechanism of the ionization and thus can be difficult to interpret.

=== Names === Nemonapride is the generic name of the drug and its INNTooltip International Nonproprietary Name and JANTooltip Japanese Accepted Name. It was also previously known as emonapride and by its former developmental code name YM 09151-2. In addition, nemonapride is known by its brand name Emilace (JPTooltip Japanese language: エミレース) in Japan and China.

The CDC defines an adult (a person aged 20 years or greater) with a body mass index (BMI) of 30 or greater as obese and an adult with a BMI of 25.0 to 29.9 as overweight. Obesity in adults is divided into three categories. Adults with a BMI of 30 to 34.9 have class 1 obesity; adults with a BMI of 35 to 39.9 have class 2 obesity; adults with a BMI of 40 or greater have class 3 obesity, which is also known as extreme or severe obesity (and was formerly known as morbid obesity). Children (persons aged 2 to 19 years) with a BMI at or above the 95th percentile of children of the same age and sex are defined as obese, and children with a BMI at or above the 85th percentile but less than the 95th percentile are defined as overweight. Compared to non-obese Americans, between 2001 and 2016, obese Americans incurred an average of $2,505 more in medical expenses annually, and in 2016, the aggregate medical cost due to obesity in the United States of America was $260.6 billion. However, some evidence suggests the lifetime cost of medical treatment for obese individuals is lower than for healthy weight individuals. This is because healthy weight people live longer statistically and tend to develop chronic diseases that need to be continually treated into old age, whereas obese people tend to die from metabolic diseases at younger ages and avoid some of those protracted medical costs.

Sources: en.wikipedia.org

Supporting material

Note that the ion strength of either C+ or A− in the mobile phase can be adjusted to shift the equilibrium position, thus retention time. The ion chromatogram shows a typical chromatogram obtained with an anion exchange column.

== Challenges and limitations == Preserved collections do not encompass all fungal diversity, and many fungal species may never be documented by preserved specimens, particularly when they remain embedded in substrates or do not produce identifiable structures for collection. As a comparatively "hidden" group, fungi are more difficult to collect than plants or animals; whereas herbarium specimens often preserve both vegetative and reproductive parts, fungaria are usually limited to reproductive sporocarps. A significant proportion of fungal biodiversity, estimated at 1.5 to 6 million species, remains unnamed and undocumented. The scientific usefulness of fungarium data can be limited by taxonomic and geographic sampling biases, including strong overrepresentation of some fungal groups and biases linked to human population density and collecting patterns. At global scale, preserved-specimen data remain concentrated in Europe, North America, and Australia and are strongly skewed toward Ascomycota, owing to persistent geographic and taxonomic biases in collecting effort. Interpretation of historical collection data can also be complicated by collecting bias, since specimens were not gathered randomly and many regions remain underrepresented. Large fractions of fungarium holdings may remain unidentified or bear outdated identifications, creating barriers to using collections effectively at scale. The main technical challenge for molecular work is the degradation of DNA over time through deamination and fragmentation.

== Clinical implications == Disposition index is used as a measure of beta cell function and the ability of the body to dispose of a glucose load. Thus a lowering of disposition index predicts the conversion of insulin resistance to diabetes mellitus type 2. Disposition index, but not insulin resistance, can predict type 2 diabetes in persons with normal blood glucose levels, but who do not have a family history (genetic predisposition) to type 2 diabetes. Disposition index can be increased by aerobic exercise, but only to the extent that insulin sensitivity is improved. The static disposition index (SPINA-DI) declines with increasing adherence to mediterranean diet. This may result from increased use of other macronutrients for the provision of energy and a reduction in the chronic stimulus for dynamical compensation with consecutive insulin hypersecretion. The disposition index is reduced in several chronic conditions including cystic fibrosis, reduced PCSK9 expression and inflammatory diseases, e.g. hidradenitis suppurativa (acne inversa).

Progesterone converts the endometrium to its secretory stage to prepare the uterus for implantation. At the same time progesterone affects the vaginal epithelium and cervical mucus, making it thick and impenetrable to sperm. Progesterone is anti-mitogenic in endometrial epithelial cells, and as such, mitigates the tropic effects of estrogen. If pregnancy does not occur, progesterone levels will decrease, leading to menstruation. Normal menstrual bleeding is progesterone-withdrawal bleeding. If ovulation does not occur, and the corpus luteum does not develop, levels of progesterone may be low, leading to anovulatory dysfunctional uterine bleeding. During implantation and gestation, progesterone appears to decrease the maternal immune response to allow for the acceptance of the pregnancy. Progesterone decreases contractility of the uterine smooth muscle. This effect contributes to prevention of preterm labor. Studies have shown that in individuals who are pregnant with a single fetus, asymptomatic in the prenatal stage, and at a high risk of giving pre-term birth spontaneously, vaginal progesterone medication has been found to be effective in preventing spontaneous pre-term birth. Individuals who are at a high risk of giving pre-term birth spontaneously are those who have a short cervix of less than 25 mm or have previously given pre-term birth spontaneously. Although pre-term births are generally considered to be less than 37 weeks, these studies found that vaginal progesterone is associated with fewer pre-term births of less than 34 weeks.

Sources: en.wikipedia.org

Frequently asked questions

Why are clinical results inconsistent?

Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.

In which countries is thymosin alpha 1 approved?

Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.

How is the peptide characterized in review articles?

Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.

What is thymosin alpha-1?

It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.

Network